Education
About Us
Working with TipRanks
Follow Us
PMV Pharmaceuticals (PMVP)
NASDAQ:PMVP
Total Valuation
PMV Pharmaceuticals has a market cap or net worth of $49.44M. The enterprise value is -$93.55M.
Market Cap$49.44M
Enterprise Value-$93.55M
Share Statistics
PMV Pharmaceuticals has 51.93M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding51.93M
Owned by Insiders3.02%
Owned by Instutions53.91%
Financial Efficiency
PMV Pharmaceuticals’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -37.83%.
Return on Equity (ROE)-33.34%
Return on Assets (ROA)-30.69%
Return on Invested Capital (ROIC)-37.83%
Return on Capital Employed (ROCE)-48.30%
Revenue Per Employee$0
Profits Per Employee-$1,249,127.66
Employee Count47
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of PMV Pharmaceuticals is -1.33. PMV Pharmaceuticals’s PEG ratio is 0.06.
PE Ratio-1.33
PS Ratio0.00
PB Ratio0.44
Price to Fair Value0.44
Price to FCF-1.50
Price to Operating Cash Flow-1.52
PEG Ratio0.06
Income Statement
In the last 12 months, PMV Pharmaceuticals had revenue of $0.00 and earned -$58.71M in profits. Earnings per share was -$0.32.
Revenue$0.00
Gross Profit-$734.00K
Operating Income-$85.45M
Pretax Income-$74.81M
Net Income-$58.71M
EBITDA-83.63M
Earnings Per Share (EPS)-0.32
Cash Flow
In the last 12 months, operating cash flow was -$51.28M and capital expenditures -$655.00K, giving a free cash flow of -$51.94M billion.
Operating Cash Flow-$51.28M
Free Cash Flow-$51.94M
Free Cash Flow per Share-$1.00
Dividends & Yields
PMV Pharmaceuticals pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-66.69%
Earnings Yield-75.38%
Stock Price Statistics
Beta1.79
52-Week Price Change-35.00%
50-Day Moving Average1.24
200-Day Moving Average1.47
Relative Strength Index (RSI)44.97
Average Volume (3m)127.76K
Important Dates
PMV Pharmaceuticals upcoming earnings date is May 8, 2025, After Close.
Last Earnings DateMar 3, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
PMV Pharmaceuticals as a current ratio of 12.22, with Debt / Equity ratio of <0.01
Current Ratio12.22
Quick Ratio12.22
Debt to Market Cap0.02
Net Debt to EBITDA0.46
Interest Coverage Ratio0.00
Taxes
In the past 12 months, PMV Pharmaceuticals has paid -$15.78M in taxes.
Income Tax-$15.78M
Effective Tax Rate21.52%
Enterprise Valuation
PMV Pharmaceuticals EV to EBITDA ratio is -0.45, with an EV/FCF ratio of -0.74.
EV to Sales0.00
EV to EBITDA-0.45
EV to Free Cash Flow-0.74
EV to Operating Cash Flow-0.74
Balance Sheet
PMV Pharmaceuticals has $169.45M in cash and marketable securities with $1.19M in debt, giving a net cash position of -$168.26M billion.
Cash & Marketable Securities$169.45M
Total Debt$1.19M
Net Cash-$168.26M
Net Cash Per Share-$3.24
Tangible Book Value Per Share$3.41
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for PMV Pharmaceuticals is $5.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$5.00
Price Target Upside426.32%
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast
EPS Growth Forecast21.33%